More than tripled risk of five-year mortality seen with use of complementary and alternative medicine alone compared with traditional therapies.

The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.

The new advice comes as federal dietary guidance has taken a much different stance. Health officials, alongside US Health Secretary Robert F. Kennedy Jr., have suggested people can include more red ...

The FDA is expected to decide on treatments for ADHD, Alzheimer disease, breast cancer, diabetes, and myasthenia gravis.

A unanimous United States Supreme Court decision has now removed a significant procedural hurdle for medical malpractice plaintiffs in 28 states. In this case, the Court was asked to determine whether ...

Three-year disease-free survival was 86.3% in the atezolizumab-mFOLFOX6 group vs 76.2% in the mFOLFOX6-alone group.

In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.

Incidence of primary end point lower for patients with target LDL level less than 55mg/dL vs less than 70mg/dL.

The Food and Drug Administration (FDA) has granted Fast Track designation to CDI-988 for treatment and prophylaxis of norovirus infection.

Postmarketing reports of fatal liver injury associated with avacopan have prompted the FDA to issue a safety alert and recommend new monitoring protocols.

Supplemental New Drug Application for at-home Igalmi aims to provide a self-administered option for agitation in schizophrenia and bipolar disorder.

Improvement in QoL, other PROs seen for those who switched to tirzepatide after not achieving glycemic control on stable dose of dulaglutide.